SINGAPORE - A drug, which aims to improve survival chances of relapsed myeloma patients, has been approved by the Health Sciences Authority (HSA).
Myeloma is an incurable blood cancer in the bone marrow or soft tissue. Symptoms include bone pain, kidney failure, and anaemia.
Already a subscriber? Log in
Read the full story and more at $9.90/month
Get exclusive reports and insights with more than 500 subscriber-only articles every month
ST One Digital
$9.90/month
No contract
ST app access on 1 mobile device
Unlock these benefits
All subscriber-only content on ST app and straitstimes.com
Easy access any time via ST app on 1 mobile device
E-paper with 2-week archive so you won't miss out on content that matters to you
